ACF Equity Research

RSS Feed

ACF Equity Research is an independent research house specialising in the highest specification independent equity research for corporate clients.

We deliver premium independent corporate sponsored equity research characterised by its accuracy, clarity and foresight based upon a fundamental valuation approach.

Our independent research is designed to educate our professional investor readers  with an emphasis on clear and accurate explanations. Our mission is to improve company’s liquidity through credible equity research services, excellent international distribution and reliable access for investment managers.

We believe in the importance and value of clarity, the careful articulation of technical ideas, concepts and solutions.

Our team of analysts are independently minded individuals who believe in thoroughness, technical competence and clear punchy communications.

Research Team ACF
  • Research Team ACF
PREMIUM
NLSP:NasdaqCM NLS Pharmaceuti...

NLS Pharmaceutics (NLSP) Core Investment Case 13022025

NLS Pharmaceutics (NLSP:NasdaqCM) is a clinical-stage Swiss foreign issuer biotech advancing the Dual Orexin Receptor Agonist (DOXA) platform, a next-generation approach to treating neurological, neurodegenerative (NDD), and metabolic disorders. The DOXA platform is designed to restore orexin signaling and modulate neuroinflammatory pathways, offering a possible market leading approach to sleep-wake disorders, ALS, and other NDDs. The DOXA platform presents a high-value opportunity for breakthro...

NLSP:NasdaqCM NLS PHARMACEUTICS
02/13/25 February 13, 2025 1 EN
Research Team ACF
  • Research Team ACF
PREMIUM
KDST.TA:TASE KADIMASTEM

Kadimastem (KDST.TA) Core Investment Case 11022025

Kadimastem (KDST.TA:TASE) is an Israeli-based clinical-stage cell therapy company pioneering regenerative medicine for insulin dependent type 1 diabetes (T1D) (no more injections) and amyotrophic lateral sclerosis (ALS). KDST has a proprietary stem-cell differentiation platform for scalable therapies designed to replace lost or damaged cells. KDST’s T1D IsletRx program aims to revolutionize insulin production for diabetes patients using off-the-shelf allogeneic encapsulated pancreatic islet cell...

02/11/25 February 11, 2025 1 EN
Research Team ACF
  • Research Team ACF
PREMIUM
SANA Sana Biotechnol...

Sana Biotechnology (SANA) Core Investment Case 05022025

Sana Biotechnology (NasdaqGS:SANA) is a well-funded cell and gene therapy innovator. Its therapies address significant unmet needs across oncology, central nervous system (CNS) disorders, and rare genetic diseases. Leveraging IP protected platform technologies, SANA is developing a robust pipeline of allogeneic cell therapies, in vivo gene editing and hypoimmune solutions, that might revolutionize treatment paradigms. SANA has a potentially transformative approach to cell and gene therapy via it...

SANA SANA BIOTECHNOLOGY
02/05/25 February 5, 2025 1 EN
Research Team ACF
  • Research Team ACF
PREMIUM
ASFH AsiaFIN Holding...

AsiaFIN Holdings Corp (ASFH) Post-Results 3Q24 03122024

AsiaFIN Holdings Corp. (OTCQB : ASFH) - aggressive growth inflection point. ASFH provides IP protected fintech solutions to ASEAN based financial institutions / corporates. 3Q24A numbers were beats for revenue, EBITDA, EBIT, EAT, adjusted Net Income and adjusted fully diluted EPS. Our post results discussion with management suggested there is a race against the clock to deliver a 4Q24E beat on our estimates, nevertheless we remain confident that revenue growth year on year will will exceed low c...

ASFH ASIAFIN HOLDINGS CORP
12/03/24 December 3, 2024 1 EN
Research Team ACF
  • Research Team ACF
PREMIUM
BCLI BRAINSTORM CELL...

BrainStorm Cell Therapeutics (BCLI) Update 11112024

BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) develops NurOwn® stem cell therapy for NDDs – BCLI’s first target is ALS (MND/Lou Gehrig’s). BLCI’s Expanded Access Program (EAP), a compassionate use study, delivered >96% probability that BCLI’s NurOwn® treatment was responsible for an improved survival rate in a test group of 10 ALS patients. BCLI recently regained Nasdaq price compliance, released two posters for NurOwn® and presented at Maxim’s healthcare summit. We infer that BCLI has a reas...

BCLI BRAINSTORM CELL THERAPEUTICS INC.
11/12/24 November 12, 2024 1 EN
ACF Healthcare
  • ACF Healthcare
COEP COEPTIS THERAPE...

Coeptistx (COEP) Deverra Deal Flash Note 21082023

Coeptis Therapeutics Inc. (NASDAQ: COEP), post Deverra deal is a Phase 1 clinical stage biotech (previously pre-clinical) in the oncology space. COEP’s exclusive license deal with Deverra for DVX201 (two products ’54’ & ‘16’ provides access to Deverra’s no-HLA-matching platform asset onto which COEP’s SNAP-CAR and GEAR platforms could dovetail’ and create a potentially very broad application set of immune technologies. Deverra’s proprietary allogeneic stem cell platform side steps patient donor ...

COEP COEPTIS THERAPEUTICS HOLDINGS INC
08/21/23 August 21, 2023 8 EN
ACF Extractives
  • ACF Extractives
IXR Ionic Rare Eart...

Ionic Rare Earths Ltd (IXR) Core Investment Case UPDATE 15082023

Ionic Rare Earths Ltd (ASX:IXR) is a rare earths mining explorer (Uganda) and REO magnet recycling company (Belfast, UK). Rare earth elements primary use is in the production of permanent magnets – key components of clean energy applications (wind turbines and electric vehicles). IXR’s flagship Makuutu Rare Earths project is significant given its ionic adsorption clayhosted geology - similar to that found in projects in Southern China, main global supplier of Heavy Rare Earths. IXR currently hol...

IXR IONIC RARE EARTHS
08/15/23 August 15, 2023 12 EN
ACF Healthcare
  • ACF Healthcare
COEP COEPTIS THERAPE...

Coeptis Therapeutics Inc. (COEP) YE22 1Q23 & DeSPAC 29062023

Coeptis Therapeutics Inc. (NASDAQ: COEP) is a pre-clinical stage biopharmaceutical Corp focused on fighting cancer via a pipeline of potentially novel products targeting CD38+ related unmet need and solid tumor cancers. The YE22A results show wash through of the SPAC merger and redemptions, which may run around ~90%. The 1Q23A results add additional insights into operational costs in particular. During YE22A raise ‘costs’ are dominated by warrant liabilities and redemptions. The diagnostics plat...

COEP COEPTIS THERAPEUTICS HOLDINGS INC
06/29/23 June 29, 2023 24 EN
ACF Mining
  • ACF Mining
SLR Silver Lake Res...
IMD IMDEX ... (+10)

ESG Sustainability Report 2023 Metals & Mining ASX - 13062023.pdf

ACF Equity Research’s ESG / Sustainability Report for ASX small and mid-cap miners is designed to help investors make fast simple initial filtering decisions. For firms it helps them identify investor messaging opportunities and support their ESG / Sustainability investor strategy. Stock price and index performance data shows that companies with ESG metrics outperform the major indices.

SLR SILVER LAKE RESOURCES
IMD IMDEX
PRU PERSEUS MINING
HAS HASTINGS TECHNOLOGY METALS
PDI PREDICTIVE DISCOVERY
BGL BELLEVUE GOLD
VUL VULCAN ENERGY RESOURCES
FEAM 5E ADVANCED MATERIALS INC
QPM QUEENSLAND PACIFIC METALS LTD
RDRUY NEOMETALS LTD
06/13/23 June 13, 2023 50 EN
ACF Energy
  • ACF Energy
KIBO KIBO ENERGY

Kibo Energy (KIBO) Flash Note Warrants Offering ACF Equity Research 19...

Kibo Energy Plc (dual listed KIBO:AIM, JSE:KBO) a renewable, reserve energy, LDES and biofuel corp., last week announced a repriced warrant offer that should unblock arious decision mechanisms (including spinoffs), which would be in the interest of the majority of investors. We note management (current + previous) is committing >£700k of its own capital via the CLN conversion. Exercising the repriced warrants on the JSE appears the logical approach. The S. African s/p arbitrage puts the repriced...

04/19/23 April 19, 2023 8 EN
PPTA PERPETUA RESOUR...

Perpetua Resources Corp. (PPTA) Core Investment Case UPDATE ACF Equity...

Perpetua Resources Corp. (Nasdaq: PPTA; TSX: PPTA) is a gold-antimony-silver deposits developer in the stable mining jurisdiction of Stibnite-Yellow Pine, Idaho. PPTA’s Stibnite open-pit gold (Au) project is one of the highest grade US deposits Compared with the 2020 FS after-tax NPV of $1.86bn (assumptions: 5% discount rate, gold $1,850/oz)  antimony (M+I 206Mlbs) is a potentially exciting byproduct. PPTA’s MCap is at an ~90% discount to the FS suggesting a significant potential mispricing. Sin...

PPTA PERPETUA RESOURCES CORP
08/19/22 August 19, 2022 12 EN
ACF Extractives
  • ACF Extractives
8GC GLENCORE PLC
KGH KGHM Polska Mie... ... (+5)

Silver Thematic ACF Equity Research 11082022

Silver (Ag) is half store of value and half industrial metal. A hawkish Federal Reserve and spiking bond yields will create significant headwinds for the Ag price 2H22E. Any expectations for global recession, leading to an industrial cycle downturn will  also push the silver price down. In 2H22E we assess that both weakening industrial activity (>50% of global silver demand) and monetary policy trends will exert downward pressure on silver’s price. Beyond YE22E the physical silver supply deficit...

8GC GLENCORE PLC
KGH KGHM POLSKA MIEDZ S.A.
FRES FRESNILLO PLC
POLY POLYMETAL INTERNATIONAL PLC
NE.M.BA NEWMONT CORPORATION
08/11/22 August 11, 2022 20 EN

Uranium Market Briefing Note FINAL 25092019

Uranium’s (U3O8) main use is as a fuel in the production of electricity by nuclear power stations. The uranium market is complex, illiquid (thinly traded) and opaque. Directly or indirectly State-controlled producers account for up to 70% of global production and these players do not have to follow economic logic unlike the companies without State subsidy. The majority of consumption (power stations) are geographically and often politically far from the majority of production (mines). Consumptio...

09/25/19 September 25, 2019 8 EN
Research Team ACF
  • Research Team ACF
PREMIUM
NOVN NOVARTIS AG
GILD Gilead Sciences... ... (+4)

ACF Insight - Innovations in Oncology - the Future of Cancer Treatment...

Global oncology spending is projected to reach US$409bn by 2028E, up from US$223bn in 2023A at a 5yr CAGR of 11.5-14.5% from 2024-2028 (IQVIA, 2024). This growth is in part driven by US spending, which has increased to $99bn in 2023A up from $65bn in 2019A - the US makes up ~45% of global oncology spending.

NOVN NOVARTIS AG
GILD GILEAD SCIENCES INC.
BMY BRISTOL-MYERS SQUIBB COMPANY
ICCM ICECURE MEDICAL LTD
07/11/24 July 11, 2024 1 EN
Research Team ACF
  • Research Team ACF
PREMIUM
HUDcxd Hudson Resource...
GROC GREENROC MINING... ... (+3)

Greenland mining

Unloved…Unknown…But Excellent? Greenland’s extraordinary potential for critical raw materials mining was again recognized in 2023, this time by the Centre for Minerals and Materials (MiMa, report published in June 2023). Greenland's stated aim is to attract greater (and sustainable) exploration and ultimately mining interest in Greenland’s estimated 400k km2 ice-free land blocks. Greenland's mineral potential is considered…vast.

HUDcxd HUDSON RESOURCES INC.
GROC GREENROC MINING PLC
PNRL PREMIUM NICKEL RESOURCES LTD
02/27/24 February 27, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch